FindTrial
Sign In

Evorpacept (ALX148)

DRUG4 trials

Sponsors

ALX Oncology Inc., University of Colorado, Denver

Conditions

Advanced CancerBreast Cancer, MetastaticGastric AdenocarcinomaGastric CancerGastroesophageal Junction AdenocarcinomaMetastatic CancerMicrosatellite Stable Metastatic Colorectal CancerNonHodgkin Lymphoma

Phase 1

A Study of Evorpacept (ALX148) in Patients With Advanced Solid Tumors and Lymphoma (ASPEN-01)
CompletedNCT03013218
ALX Oncology Inc.Metastatic Cancer, Solid Tumor, Advanced Cancer +1
Start: 2017-02-03End: 2025-07-08Updated: 2025-08-01

Phase 2

A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
Active, not recruitingNCT05002127
ALX Oncology Inc.Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma
Start: 2022-01-15End: 2026-06-30Updated: 2025-08-07
Study of Evorpacept (ALX148) With Cetuximab and Pembrolizumab for Refractory Microsatellite Stable Metastatic Colorectal Cancer
TerminatedNCT05167409
University of Colorado, DenverMicrosatellite Stable Metastatic Colorectal Cancer
Start: 2022-07-28End: 2024-10-30Updated: 2026-09-03
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RecruitingNCT07007559
ALX Oncology Inc.Breast Cancer, Metastatic
Start: 2025-12-10End: 2028-12-01Target: 120Updated: 2026-08-14

Related Papers

Evorpacept plus rituximab for the treatment of relapsed or refractory non-Hodgkin lymphoma: results from the phase I ASPEN-01 study
Haematologica2025-04-104 citations
Final analysis of the randomized phase 2 part of the ASPEN-06 study: A phase 2/3 study of evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with HER2-overexpressing gastric/gastroesophageal cancer (GC).
Journal of Clinical Oncology2025-01-2710 citations
Results of a phase 2 study of evorpacept (E, ALX148), cetuximab (C), and pembrolizumab (P) in patients with refractory microsatellite stable metastatic colorectal cancer (MSS CRC).
Journal of Clinical Oncology2024-06-011 citations
Trial in progress: A phase II study (with safety run-in) of evorpacept (ALX148), cetuximab, and pembrolizumab in patients with refractory microsatellite-stable metastatic colorectal cancer (AGICC-ALX148 21CRC01).
Journal of Clinical Oncology2023-01-24
Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
2021-11-1594 citations
498 Evorpacept (ALX148), a CD47 myeloid checkpoint inhibitor, in patients with head and neck squamous cell carcinoma (HNSCC) and with gastric/gastroesophageal cancer (GC); ASPEN-01
Regular and Young Investigator Award Abstracts2021-11-018 citations
404 ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction (GC) cancer and head and neck squamous cell carcinoma (HNSCC)
Regular and Young Investigator Award Abstracts2020-11-011 citations
A phase I study of ALX148, a CD47 blocker, in combination with standard anticancer antibodies and chemotherapy regimens in patients with advanced malignancy.
Journal of Clinical Oncology2020-05-2019 citations
A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin Lymphoma
Blood2019-11-1325 citations
A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.
Journal of Clinical Oncology2019-05-2018 citations
A phase 1 study of ALX148, a CD47 blocker, alone and in combination with established anticancer antibodies in patients with advanced malignancy and non-Hodgkin lymphoma.
Journal of Clinical Oncology2018-05-2020 citations
ALX148 Is a High Affinity Sirpα Fusion Protein That Blocks CD47, Enhances the Activity of Anti-Cancer Antibodies and Checkpoint Inhibitors, and Has a Favorable Safety Profile in Preclinical Models
Blood2017-12-078 citations